[1]薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变（PDR）的疗效分析[J].眼科新进展,2017,37(5):458-462.[doi:10.13389/j.cnki.rao.2017.0116]
　XUE Peng-Cheng,YOU Zhi-Peng,FU Shu-Hua,et al.Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(5):458-462.[doi:10.13389/j.cnki.rao.2017.0116]
点击复制

23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变（PDR）的疗效分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年5期
页码:
458-462
栏目:
应用研究
出版日期:
2017-05-05

文章信息/Info

Title:
Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy
作者:
薛鹏程; 游志鹏; 付书华; 彭灵; 董乐
330006　江西省南昌市，南昌大学第二附属医院眼科
Author(s):
XUE Peng-Cheng; YOU Zhi-Peng; FU Shu-Hua; PENG Ling; DONG Le
Department of Ophthalmology，the Second Affiliated Hospital，Nanchang University，Nanchang 330006，Jiangxi Province，China
关键词:
23G玻璃体切割; 康柏西普; 增生型糖尿病视网膜病变; 血管内皮生长因子
Keywords:
23G vitrectomy; conbercept; proliferative diabetic retinopathy; vascular endothelial growth factor
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2017.0116
文献标志码:
A
摘要:
目的　对比分析23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普对增生型糖尿病视网膜病变（proliferative diabetic retinopathy，PDR）疗效及手术相关并发症的影响。方法　回顾性分析南昌大学第二附属医院2015年1月至2016年2月收治的PDR患者42例（42眼）的资料，其中22例在行23G玻璃体切割术前1周于玻璃体内注射康柏西普0.05 mL（A组）；另外20例在行23G玻璃体切割术完毕时于玻璃体内注射康柏西普0.05 mL（B组）。观察两组患眼手术时间，术后玻璃体内出血情况，术中、术后其他指标及最佳矫正视力等的差异。结果　A组手术完成时间、电凝止血率、医源性裂孔发生率及术中出血率均低于B组。两组术后6个月视力比较差异无统计学意义（P>0.05），但两组术前、术后视力相比差异均有统计学意义（均为P<0.05）。术后早期玻璃体出血（≤1个月）；A组有4眼（18.2%），B组有3眼（15.0%），两组相比差异无统计学意义（P>0.05）。术后晚期玻璃体出血（>1个月）；A组6眼（27.3%），B组未发现玻璃体内出血，两组相比差异有统计学意义（P<0.05）。随访期间A组有3眼因术后玻璃体再出血，需再次手术，再次手术率13.6%；B组有2眼术后发生牵拉性视网膜脱离，需再次手术治疗，再次手术率10.0%。视网膜激光光凝补充治疗：A组需（2.3±1.0）次，B组需（1.4±0.6）次，两组比较差异有统计学意义（P<0.05）。结论　23G玻璃体切割术中联合康柏西普治疗PDR可有效预防术后早晚期出血，为术后激光补充治疗提供有利条件，减少激光补充治疗次数；而术前联合康柏西普治疗PDR可缩短手术时间，减少术中并发症发生，降低术后早期出血率。
Abstract:
Objective　To discuss the effects and influence of preoperative and postoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy （PDR）.Methods　 A retrospective research was performed on 42 PDR eyes from January 2015 to February 2016 in the Second Affiliated Hospital of Nanchang University，who received either intravitreal 0.05 mL conbercept injection 7 days before 23G vitrectomy （group A，n=22） or intravitreal 0.05 mL conbercept injection at the end of 23G vitrectomy （group B，n=20）.The operative time，postoperative vitreous hemorrhage （VH），intraoperative and postoperative other differences of clinical indicators and postoperative best-corrected visual acuity （BCVA） between the two groups were compared.Results　The average operation time，intraoperative electric coagulation hemostasis rate，iatrogenic hiatal incidence and intraoperative hemorrhage rate of group A were lower than those of group B （all P<0.05）． BCVA at 6 months after surgery did not differ significantly between two groups （P>0.05），but the difference was statistically significant between pre-operation and post-operation （P<0.05）.〖JP2〗The incidences of early （≤1 month） postoperative VH were 18.2% （4 eyes） and 15.0% （3 eyes）〖JP〗 in group A and B，respectively （P>0.05）.The incidences of later （>1 month） postoperative VH were 27.3% （6 eyes） and 0 in group A and B，respectively，the difference was statistically significant （P<0.05）.The percentages of reoperation were 13.6%（3 eyes with postoperative VH） and 10.0%（2 eyes with traction retinal detachment） respectively in group A and B.The average times of supplementary laser photocoagulation were（2.3±1.0）times and（1.4±0.6）times in group A and B，respectively in follow-up period （P<0.05）.Conclusion　The adjunctive use of intraoperative intravitreal injection of conbercept can prevent effectively postoperative VH and decrease conveniently the time of supplementary laser photocoagulation in 23G vitrectomy for PDR，as well as the preoperative adjunctive use can decrease the operation time，intraoperative complications and incidences of early postoperative VH.

参考文献/References:

［1］　VAN GEEST RJ，LESNIK-OBERSTEIN SY，TAN HS，MURA M，GOLDSCHMEDING R，NOORDEN CJFV，et al.A shift in the balance of vascular endothelia growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy ［J］.Br J Ophthalmol，2012，96（4）：587-590.
［2］　HUANG YH，YEH PT，CHEN MS，YANG CH，YANG CM.Intravitreal IVB and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage［J］.Retina，2009，29（8）：1134-1140.
［3］　YEH PT，YANG CH，YANG CM.Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy［J］.Acta Ophthalmol，2011，89（7）：634-640.
［4］　ZHANG M，YU D，YANG C，XIA Q，LI W，LIU B，et al.The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization［J］.Pharm Res，2009，26（1）：204-210.
［5］　LIM LS，LIEW G，CHEUNG N，MITCHELL P，WONG TY.Mixed messages on systemic therapies for diabetic retinopathy［J］.Lancet，2010，376（9735）：124-136.
［6］　AJVAZI H.Proliferative diabetic retinopathy-results of the microsurgical and laser treatment［J］.Med Arch，2010，64（3）：165-167.
［7］　AHN J，WOO SJ，CHUNG H，PARK KH.The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy［J］.Ophthalmology，2011，118（11）：2218-2226.
［8］　章晖，叶波，邱新文，兰丽霞，任旋，刘伟.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变［J］.眼科新进展，2014，34（10）：975-977.
ZHANG H，YE B，QIU XW，LAN LX，REN X，LIU W.Ranibizumab assisted 23G vitrectomy for proliferative diabetic retinopathy［J］.Rec Adv Ophthalmol，2014，34（10）：975-977.
［9］　魏雁涛，蒋欣桐，张钊填，周学智，邱梭，杨渊喆，等.玻璃体腔注射雷珠单抗对增生型糖尿病视网膜病变患眼微创玻璃体切割手术及手术后视力的影响［J］.中华眼底病杂志，2015，31（4）：337-340.
WEI YT，JIANG XT，ZHANG ZT，ZHOU XZ，QIU S，YANG YZ，et al.The effect of microincision vitrectomy and intravitreal injection of ranibizumab in the treatment of proliferative diabetic retinopathy［J］.Chin J Ocul Fundus Dis，2015，31（4）：337-340.
［10］　FUNATSU H，YAMASHITA H，MIMURA T，NOMA H，NAKAMURA S，HORI S.Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines［J］.Eye，2006，21（3）：377-382.
［11］　STEFANSSON E.The therapeutic effects of retinal laser treat ment and vitrectomy.A theory based on oxygen and vascular physiology［J］.Acta Ophthalmol Scand，2001，79（5）：435-440.
［12］　陈晶华，黎晓新，姜燕荣.增殖性糖尿病视网膜病变玻切术后再出血原因分析及处理［J］.中国实用眼科杂志，2000，18（2）：83-84.
CHEN JH，LI XX，JIANG YR.Analysis and treatment of rehemorrhage in eyes with proliferative diabetic retinopathy after vitrectomy［J］.Chin J Pract Ophthalmol，2000，18（2）：83-84.
［13］　ZHANG M，ZHANG J，YAN M，HONG L，YANG C，YU D.Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys ［J］.Mol Vis，2008，14：37-49.
［14］　CHIN HS，PARK TS，MOON YS，OH JH.Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes［J］.Retina，2005，25（5）：556-560.
［15］　CHEEMA RA，MUSHTAQ J，ALKHARS W，ALASKAR E，CHEEMA MA.Role of intravitreal bevacizumab（Avastin） injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage［J］.Retina，2010，30（10）：1646-1650.
［16］　DONG HP，SHIN JP，SI YK.Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage：a comparative study［J］.Graefes Arch Clin Exp Ophthalmol，2010，248（10）：641-650.
［17］　HOLM K，SCHROEDER M，LVESTAM AM.Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema［J］.Doc Ophthalmol，2015，131（1）：43-51.
［18］　FERRONE PJ，JONISCH J.Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema：a randomized，clinical trial［J］.Ophthalmic Surg Lasers Imaging Retina，2016，47（6）：536-543.

相似文献/References:

[1]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(5):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[2]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(5):172.[doi:10.13389/j.cnki.rao.2016.0047]
[3]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
[4]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(5):725.[doi:10.13389/j.cnki.rao.2016.0192]
[5]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(5):751.[doi:10.13389/j.cnki.rao.2016.0200]
[6]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(5):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[7]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
　WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(5):1172.[doi:10.13389/j.cnki.rao.2016.0312]
[8]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
[9]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658.[doi:10.13389/j.cnki.rao.2017.0167]
　LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(5):658.[doi:10.13389/j.cnki.rao.2017.0167]
[10]尹妮,赵帅,朱红娜.康柏西普预处理联合玻璃体切割术治疗增生型糖尿病视网膜病变[J].眼科新进展,2017,37(8):770.[doi:10.13389/j.cnki.rao.2017.0195]
　YIN Ni,ZHAO Shuai,ZHU Hong-Na.Conbercept pre-treatment combined with vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(5):770.[doi:10.13389/j.cnki.rao.2017.0195]

更新日期/Last Update: 2017-06-07